Metabotropic glutamate (mGlu) receptors have received much attention, driven by a strong
belief in the potential of these modulatory glutamate receptors as drug targets. So far, major …

Schizophrenia is associated with disruptions in N-methyl-D-aspartate glutamate receptor
subtype (NMDAR)-mediated excitatory synaptic signaling. The metabotropic glutamate …

Psychiatric and neurological disorders are linked to changes in synaptic excitatory processes
with a key role for glutamate, that is, the most abundant excitatory amino-acid. Molecular …

Positive allosteric modulators (PAMs) of metabotropic glutamate receptor subtype 5 (mGlu 5
) have emerged as an exciting new approach for the treatment of schizophrenia and other …

We examined the pharmacological profile of (3,4-dihydro-2H-pyrano[2,3]b quinolin-7-yl) (cis-4-methoxycyclohexyl)
methanone (JNJ16259685). At recombinant rat and human …

Advanced leads from a series of 1,2,4-triazolo[4,3-a]pyridines with mGlu2 receptor PAM
activity are reported. By modification of the analogous imidazo[1,2-a]pyridine series, the newly …

The α 7 nicotinic acetylcholine receptor (nAChR) is a potential therapeutic target for the
treatment of cognitive deficits associated with schizophrenia, Alzheimer's disease, Parkinson's …

R214127 was shown to be a potent and noncompetitive metabotropic glutamate 1 (mGlu1)
receptor-selective antagonist. The kinetics and pharmacology of [ 3 H]1-(3,4-dihydro-2H-…

Imidazo[1,2-a]pyridines were identified via their shape and electrostatic similarity as novel
positive allosteric modulators of the metabotropic glutamate 2 receptor. The subsequent …

The synthesis and in vitro and in vivo evaluation of a new series of 7-(phenylpiperidinyl)-1,2,4-triazolo[4,3-a]pyridines,
which were conveniently radiolabeled with carbon-11, as …